Heart Rate Variability and Its Associations with Organ Complications in Adults after Fontan Operation

Magdalena Okólska 1, Jacek Łach 2, Paweł T. Matusik 3,*, Jacek Pająk 4, Tomasz Mroczek 5, Piotr Podolec 2 and Lidia Tomkiewicz-Pająk 2

1 Cardiological Outpatient Clinic, Department of Cardiovascular Diseases, John Paul II Hospital, 31-202 Krakow, Poland; m.okolska@interia.pl
2 Department of Cardiac and Vascular Diseases, Institute of Cardiology, Jagiellonian University Medical College, John Paul II Hospital, 31-202 Krakow, Poland; djholter@interia.pl (J.L.); ppodolec@interia.pl (P.P.); ltom@wp.pl (L.T.-P)
3 Department of Electrocardiology, Institute of Cardiology, Faculty of Medicine, Jagiellonian University Medical College, John Paul II Hospital, 31-202 Krakow, Poland
4 Department of Pediatric Heart Surgery and General Pediatric Surgery, Medical University of Warsaw, 02-091 Warsaw, Poland; jacekpajak@poczta.onet.pl
5 Department of Pediatric Cardiac Surgery, Jagiellonian University, 30-663 Krakow, Poland; t_mroczek@hotmail.com
* Correspondence: pawel.matusik@wp.eu; Tel.: +48-12-614-23-81

Abstract: Reduction of heart rate variability (HRV) parameters may be a risk factor and precede the occurrence of arrhythmias or the development of heart failure and complications in people with postinfarct left ventricular dysfunction and after coronary artery bypass grafting. Data on this issue in adults after a Fontan operation (FO) are scarce. This study assessed the association between HRV, exercise capacity, and multiorgan complications in adults after FO. Data were obtained from 30 FO patients (mean age 24 ± 5.4 years) and 30 healthy controls matched for age and sex. HRV was investigated in all patients by clinical examination, laboratory tests, echocardiography, a cardiopulmonary exercise test, and 24-h electrocardiogram. The HRV parameters were reduced in the FO group. Reduced HRV parameters were associated with patients’ age at the time of FO, time since surgery, impaired exercise capacity, chronotropic incompetence parameters, and multiorgan complications. Univariate analysis showed that saturated O2 at rest, percentage difference between adjacent NN intervals of >50 ms duration, and peak heart rate were associated with chronotropic index. Multivariable analysis revealed that all three variables were independent predictors of the chronotropic index. The results of this study suggest novel pathophysiological mechanisms that link HRV, physical performance, and organ damage in patients after FO.

Keywords: heart rate variability; physical performance; Fontan operation; organ complications

1. Introduction

The Fontan operation (FO) is the treatment of choice for patients with single-ventricle congenital heart disease [1]. The aim of this operation is to separate the pulmonary and systemic circulation, and achieve normal or near-normal arterial oxygen saturation. However, over time, cardiac and extra-cardiac complications develop in patients after FO. The literature also provides reports on the development of pathophysiological abnormalities, including abnormal functioning of the autonomic nervous system, altered chemoreceptor activity, and neurohumoral disorders, in this patient population [2–4].

One of the most significant problems in clinical practice during follow-up is identifying patients with a high risk of mortality. Parallel to the use of well-known methods (such as echocardiography), new methods are being developed, but their promising diagnostic or prognostic value is still not fully understood. Assessment of heart rate variability (HRV) is one such method.
A severe decrease in HRV indicates autonomic nervous system (ANS) dysfunction [5]. Decreased HRV may be a risk factor and precede organ complications. Research on patients with postinfarct left ventricular dysfunction indicates a relationship between reduced HRV and the development of heart failure, a higher risk of ventricular arrhythmia, and a worse prognosis [6,7]. HRV reduction is also observed in patients after cardiac surgery [8]. In adults with congenital heart disease, reduced HRV parameters were found among those with tetralogy of Fallot, systemic right ventricle, or cyanotic heart disease and those who underwent aortic coarctation repair or ventricular septal defect closure with right bundle branch block [9–12]. However, only a few studies have analyzed these aspects in patients after FO, and thus the data are limited. Furthermore, literature reports are mostly related to a pediatric population [13–18], while data regarding adult patients are scarce.

Therefore, this study aimed to assess the relationship between HRV parameters, exercise capacity, and multiorgan complications in adults after FO.

2. Materials and Methods

2.1. Study Participants

This was a retrospective study and included 30 adult patients over 18 years of age. All the patients underwent FO as they were diagnosed with functionally single ventricular heart. The patients remained under medical supervision in John Paul II Hospital. The exclusion criteria of the study were as follows: diagnosis of pulmonary artery hypertension requiring vasodilator therapy, asthma, atrial flutter, atrial fibrillation, diabetes, current infection, inflammation, and neoplastic disease, major trauma, pregnancy, use of vitamin K antagonists or beta-blockers, and history of pacemaker placement and alcohol abuse. Healthy, age- and sex-matched volunteers were included in the control group.

All the demographic, anatomic, and clinical data required for the study were obtained from the patients’ medical records. Each patient was subjected to a physical examination as well as an assessment of body mass index, ejection fraction of the systemic ventricle, and arterial oxygen saturation. Body mass index was calculated by dividing the weight of the patient (kg) by height (m²). Oxygen saturation was measured by pulse oximetry while breathing room air.

2.2. Echocardiography

Ejection fraction of the systemic ventricle was assessed using Simpson’s method. In addition, valvular competence was evaluated in all the patients by two experienced, independent cardiologists using echocardiography (Vivid 7, GE Medical Systems, Milwaukee, WI, USA), as previously described [19].

2.3. Laboratory Investigations

After overnight fasting for at least 12 h, blood samples were collected from the antecubital vein of patients. The samples were evaluated for the following laboratory parameters that may indicate multi-organ complications: white blood cell count, red blood cell count, hemoglobin concentration, hematocrit, red blood cell distribution width, platelet count, mean platelet volume (MPV), total protein, alanine aminotransferase, aspartate transaminase, gamma-glutamyl transpeptidase (GGTP), alkaline phosphatase, total bilirubin α-fetoprotein, creatinine, cystatin C and N-terminal pro-B-type natriuretic peptide. All of them were assessed by routine laboratory techniques.

2.4. Cardiopulmonary Exercise Test

Exercise tolerance was determined by performing the cardiopulmonary exercise test (CPET) using a modified Bruce protocol (Reynolds Medical System, ZAN-600, Hertford, UK). The following parameters were recorded during CPET: blood pressure, rest oxygen saturation (Sat. O₂ rest), 12-lead electrocardiogram, time of exercise, minute ventilation (VE), peak oxygen uptake (VO₂ peak), respiratory exchange ratio (RER), peak ventilatory equivalent of oxygen (VE/VO₂), peak ventilatory equivalent of carbon dioxide (VE/VCO₂),
and breathing reserve.VO₂ peak was estimated as the highest oxygen uptake at peak exercise (mL/kg/min), and the percentage of the predicted value was calculated. Ventilatory anaerobic threshold was measured using the V-slope method. VE/VO₂ was defined as the amount of ventilation needed to uptake a given amount of oxygen, while VE/VCO₂ was defined as the amount of ventilation needed to eliminate a given amount of carbon dioxide. RER was calculated by dividing VO₂ by VCO₂.

2.5. Chronotropic Incompetence

Chronotropic index was determined based on the chronotropic metabolic relationship introduced by Wilkoff et al. [20] and calculated by using the following formula: (peak heart rate − resting heart rate)/(220 − age − resting heart rate). Chronotropic incompetence was defined as a chronotropic index value of <0.8.

Heart rate reserve (HRR) was calculated as the difference between maximal heart rate (HRmax) and peak heart rate. HRmax was determined using the following formula: 220 − age. Accordingly, HRR was calculated as follows: HRR = HRmax − peak heart rate = 220 − age − peak heart rate [21,22].

2.6. Ambulatory 24-h Holter Electrocardiogram

All patients and controls were subjected to standard 24-h electrocardiographic monitoring during daily activity, using a commercially available Holter system. All Holters were reviewed by two experienced observers. All recordings were analyzed using a PC-based Holter system, and those shorter than 21 h were excluded. The predominant rhythm was defined as the one that was present during >50% of the time during the Holter recording.

2.7. Heart Rate Variability

All Holters with available data were reviewed by two experienced analysts to analyze HRV. The beats were classified by automated software as normal, supraventricular extrasystolic, ventricular extrasystolic, those of uncertain origin, or artifacts. The classification was manually reviewed and corrected if necessary. Only normal-to-normal (NN) intervals were included in the HRV analysis.

The following HRV time-domain parameters were measured: standard deviation of all NN intervals (SDNN), standard deviation of the averages of NN intervals in all 5-min segments of the entire recording (SDANN), root mean square of the differences of successive NN intervals (rMSSD), percentage difference between adjacent NN intervals of >50 ms duration (pNN50), and HRV triangular index.

Furthermore, the following HRV frequency parameters were measured: very low frequency (0.017–0.050 Hz); low frequency (0.050–0.150 Hz); and high frequency (0.150–0.350 Hz). The high frequency component is associated with the activity of the parasympathetic nervous system, and low frequency with both the sympathetic and parasympathetic system. Very low frequency is related to more long-term fluctuations in heart rate [23].

The total power was determined at frequencies ranging from 0.017 to 0.050 Hz. In addition, the low frequency/high frequency ratio was calculated. All spectral indexes were calculated as average data over the complete recording period (up to 24 h). The parameters SDNN, HRV triangular index, total power, and low frequency were assumed to reflect, with some simplification, the overall HRV or activity of both sympathetic and parasympathetic components of the ANS, while the parameters rMSSD, pNN50, and high frequency were directly proportional to the parasympathetic nervous system [23].

2.8. Statistical Analysis

The data distribution was presented as numbers and percentages for categorical variables, means with SDs for normally distributed continuous variables, and medians with lower and upper quartiles (Q1-Q3) for continuous variables with non-normal distribution. The normality of the data distribution was verified using the Kolmogorov–Smirnov test. Quantitative variables of patients who underwent FO and control participants were com-
pared using the two-tailed Student’s t-test or Mann–Whitney U test, whereas qualitative variables were analyzed using the chi-square test. The association between numerical variables was analyzed by calculating the Pearson’s correlation or Spearman’s rank correlation coefficient. Moreover, the simultaneous influence of Sat. O₂ rest and pNN50 on peak heart rate was assessed using the linear regression model. The results were presented as coefficient (b) with 95% confidence interval. The R-square value was calculated to describe the goodness-of-fit for the linear regression model. All the analyses were performed using IBM SPSS Statistics for Windows, Version 25.0 (IBM Corp., Armonk, NY, USA). Statistical significance was defined as p < 0.05 for the two-tailed test.

3. Results

3.1. Patients’ Characteristics

Thirty adult patients who underwent FO were enrolled in the study, including 17 men (57%) with a mean age of 24 ± 5.4 years. These patients did not show any significant difference from the controls with regard to age, sex, and body mass index. The median age of patients at the time of surgery was 3 (Q1–Q3: 2–5) years, the median time after surgery was 19.5 (Q1–Q3: 17–21) years. A total of 19 (64%) patients had fenestration, and 11 (36%) had no fenestration. The mean ejection fraction of the systemic ventricle was 52 ± 9.1%. The baseline characteristics of the study group and the control group are presented in Tables 1 and 2.

Table 1. Baseline characteristics of the study group and controls.

| Variables                  | Fontan Patients (n = 30) | Controls (n = 30) | p-Value |
|----------------------------|-------------------------|------------------|---------|
| Age, years                 | 24 (5.4)                | 25.6 (3.8)       | 0.23    |
| Female sex, n (%)          | 13 (43)                 | 12 (40)          | 0.95    |
| Height, cm                 | 170 (8.1)               | 173 (6.9)        | 0.19    |
| Weight, kg                 | 65.08 (9.7)             | 69.0 (9.3)       | 0.85    |
| Body mass index, kg/m²     | 22.5 (2.7)              | 22.7 (2.2)       | 0.69    |

Continuous data are presented as mean (SD) and categorical data as number (percentage).

3.2. Laboratory Tests Results

The laboratory parameters determined for the FO group and the control group are presented in Table 3.

Table 2. Baseline characteristics of patients after the Fontan operation.

| Variables                          | Patients (n = 30) |
|------------------------------------|------------------|
| Anatomic diagnosis, n (%)          |                  |
| Tricuspid atresia                  | 5 (17)           |
| Pulmonary stenosis/TGA             | 4 (13)           |
| Right ventricular hypoplasia       | 11 (36)          |
| Hypoplastic left heart syndrome    | 5 (17)           |
| Double-outlet right ventricle with left ventricular hypoplasia | 3 (10) |
| Double-inflow left ventricle       | 1 (4)            |
| Common atrioventricular canal      | 1 (4)            |
| Systemic ventricle type, n (%)     |                  |
| Left ventricle                     | 24 (80)          |
| Right ventricle                    | 6 (20)           |
Table 2. Cont.

| Variables                          | Patients (n = 30) |
|------------------------------------|------------------|
| NYHA functional class, n (%)       |                  |
| I                                  | 5 (17)           |
| II                                 | 21 (71)          |
| III                                | 4 (12)           |
| IV                                 | 0 (0)            |
| Types of Fontan operation, n (%)   |                  |
| Total cavopulmonary connection, lateral tunnel | 29 (96) |
| Atriopulmonary connection          | 1 (4)            |

Abbreviation: NYHA, New York Heart Association; TGA, transposition of great arteries.

Table 3. Laboratory parameters in patients after Fontan procedure and in controls.

| Variables                          | Fontan Group (n = 30) | Controls (n = 30) | p-Value |
|------------------------------------|-----------------------|-------------------|---------|
| NT-proBNP, pg/mL                   | 148.0 (96.0–470.0)    | 24.5 (6.0–35.0)   | <0.001  |
| RBC, 10⁹/µL                        | 5.5 (0.6)             | 4.9 (0.5)         | <0.001  |
| Hemoglobin, g/dL                   | 18.8 (1.8)            | 14.7 (1.3)        | 0.011   |
| Hematocrit, %                      | 47.6 (4.5)            | 43.0 (3.3)        | <0.001  |
| RDW, %                             | 13.2 (12.9–14.4)      | 12.4 (12.0–12.6)  | <0.001  |
| Platelet count, 10³/µL             | 164.4 (70.8)          | 228.2 (38.1)      | <0.001  |
| PDW, fl                            | 16.0 (3.2)            | 12.2 (2.3)        | <0.001  |
| MPV, fl                            | 12.0 (1.2)            | 10.4 (1.0)        | <0.001  |
| Cystatin C, mg/L                   | 0.9 (0.2)             | 0.8 (0.1)         | 0.009   |
| Creatinine, µmol/L                 | 72.8 (12.9)           | 77.4 (14.2)       | 0.19    |
| eGFR, mL/min/1.73 m²               | 116.5 (13.6)          | 112.0 (12.9)      | 0.26    |
| AST, IU/L                          | 24.0 (20.0–28.0)      | 19.5 (17.0–22.0)  | <0.001  |
| ALT, IU/L                          | 24.0 (19.0–27.0)      | 20.0 (17.0–23.0)  | 0.04    |
| GGTP, U/L                          | 61.5 (44.0–117.0)     | 15.5 (14.0–18.0)  | <0.001  |
| Bilirubin, µmol/L                  | 18.3 (10.7–34.0)      | 12.0 (7.7–17.0)   | 0.002   |
| α-Fetoprotein, ng/mL               | 2.5 (1.9–3.6)         | 2.3 (1.9–3.4)     | 0.657   |
| ALP, U/L                           | 80.5 (64.0–88.0)      | 67.0 (55.0–89.0)  | 0.11    |
| Total protein, g/dL                | 75.1 (70.2–78.8)      | 75.0 (73.0–78.6)  | 0.43    |
| Prothrombin time, s                | 13.6 (12.6–15.2)      | 11.9 (11.4–12.0)  | <0.001  |
| INR                                | 1.2 (1.2–1.65)        | 1.0 (0.9–1.1)     | <0.001  |
| AST/ALT ratio                      | 1.1 (0.4)             | 1.0 (0.3)         | 0.21    |

Continuous data are presented as mean (SD) or median (Q1–Q3). Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AST/ALT ratio, ratio of aspartate transaminase to alanine transaminase; eGFR, estimated glomerular filtration rate; GGTP, γ-glutamyl transpeptidase; INR, international normalized ratio; MPV, mean platelet volume; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PDW, platelet distribution width; RBC, red blood cells; RDW, red cell distribution width.

3.3. CPET Results

The CPET results of patients from the FO group were compared with those from the control group and are presented in Table 4.
Table 4. Cardiopulmonary exercise test results of patients in the Fontan operation group and controls.

| Variables                  | Fontan Group (n = 30) | Controls (n = 30) | p-Value |
|---------------------------|-----------------------|-------------------|---------|
| Exercise time, min        | 13.5 (3.4)            | 16.65 (2.7)       | <0.001  |
| Sat. $O_2$ rest, %        | 92.0 (89.0–93.0)      | 97.0 (96.0–98.0)  | <0.001  |
| Sat. $O_2$ exercise, %    | 87.0 (84.0–89.0)      | 97.0 (96.0–97.0)  | <0.001  |
| Peak VO$_2$ per kg, mL/kg/min | 20.6 (18.2–23.2) | 50.9 (46.5–54.1)  | <0.001  |
| Peak VO$_2$, % of predicted | 55.0 (48.0–63.0) | 97.0 (95.0–98.0)  | <0.001  |
| VE                        | 46.0 (35.0–63.0)      | 123 (97–138)      | <0.001  |
| VE/VCO$_2$, L/L           | 33.3 (3.9)            | 26.5 (2.9)        | <0.001  |
| RER peak                  | 1.0 (0.08)            | 1.1 (0.9)         | 0.01    |
| Chronotropic index        | 0.55 (0.47–0.62)      | 0.93 (0.88–0.99)  | <0.001  |
| HRR                       | 32.0 (24.0–60.0)      | 8.0 (1.0–14.0)    | <0.001  |

Continuous data are presented as mean (SD) or median (Q1–Q3). Abbreviations: HRR, heart rate reserve; peak VO$_2$ per kg, peak oxygen uptake per kilogram; peak VO$_2$, percentage of predicted value for peak oxygen uptake; RER peak, peak respiratory exchange ratio; Sat. $O_2$, oxygen saturation; VE, minute ventilation; VE/VCO$_2$, peak ventilatory equivalent of CO$_2$.

3.4. Heart Rate Variability

A significant reduction in HRV was observed in adult patients with Fontan circulation compared with the control subjects (Table 5).

Table 5. Heart rate and HRV in the Fontan patients and control subjects.

| Variables                  | Fontan Patients (n = 30) | Controls (n = 30) | p-Value |
|---------------------------|-------------------------|-------------------|---------|
| Heart rate, bpm           | 69.1 (10.4)             | 80.5 (6.5)        | <0.001  |
| Mean NN, ms               | 922.0 (157.9)           | 771.57 (59.4)     | <0.001  |
| SDNN, ms                  | 121.8 (29.6)            | 152.74 (23.94)    | <0.001  |
| SDANN, ms                 | 111.9 (31.6)            | 133.63 (25.2)     | <0.001  |
| rMSSD, ms                 | 16.5 (10.9–33.5)        | 32.65 (27.4–43.7) | <0.001  |
| pNN50, ms                 | 6.75 (2.7–13.0)         | 11.8 (7.2–13.2)   | 0.018   |
| HRV triangular index, ms  | 34.5 (11.3)             | 45.7 (7.8)        | <0.001  |
| Very low frequency (ms$^2$) | 301.6 (13.1–491.2) | 491.8 (256.2–71.2) | 0.030   |
| Low frequency (ms$^2$)     | 332.8 (93.4–551.2)      | 712.3 (538.3–1129.1) | <0.001  |
| High frequency (ms$^2$)    | 140.1 (46.1–303.2)      | 289.0 (156.7–370) | 0.019   |
| Total power (ms$^2$)       | 861.1 (1.0–1738.0)      | 1618.7 (957.4–2031) | 0.003   |
| Low frequency/high frequency ratio | 3.5 (2.5) | 4.2 (1.5)        | 0.190   |

Continuous data are presented as mean (SD) or median (Q1–Q3). Abbreviations: HRV, heart rate variability; NN, normal-to-normal interval; pNN50, percentage difference between adjacent NN intervals of >50 ms duration; rMSSD, root mean square of the differences of successive NN intervals; SDANN, standard deviation of the averages of NN intervals in all 5-min segments of the entire recording; SDNN, standard deviation of all NN intervals.

The correlations between the HRV parameters and patients’ characteristics are presented in Table 6.
Table 6. Correlations between HRV parameters and patient characteristics.

| HRV Parameters | SDNN | HRV Index | Low Frequency | Total Power | rMSSD | pNN50 | High Frequency |
|----------------|------|-----------|---------------|-------------|-------|-------|---------------|
| Overall HRV or Sympathetic and Parasympathetic Nervous System Activities | | | | | | | |
| Parasympathetic Nervous System Activity | | | | | | | |
| Group characteristic | | | | | | | |
| Age at the time of Fontan operation | R = −0.379, p = 0.039 | R = −0.250, p = 0.183 | R = −0.074, p = 0.697 | R = −0.153, p = 0.421 | R = 0.270, p = 0.149 | R = −0.422, p = 0.020 | R = −0.047, p = 0.805 |
| Age during the study | R = −0.426, p = 0.019 | R = −0.217, p = 0.25 | R = −0.31, p = 0.094 | R = −0.432, p = 0.017 | R = −0.061, p = 0.749 | R = −0.481, p = 0.007 | R = −0.205, p = 0.276 |
| Echocardiography | | | | | | | |
| Ejection fraction of the systemic ventricle | R = 0.584, p = 0.001 | R = 0.424, p = 0.02 | R = 0.347, p = 0.06 | R = 0.453, p = 0.012 | R = 0.032, p = 0.104 | R = 0.638, p = 0.001 | R = 0.281, p = 0.132 |
| HRR | R = −0.137, p = 0.471 | R = −0.411, p = 0.023 | R = −0.221, p = 0.240 | R = −0.264, p = 0.159 | R = −0.323, p = 0.082 | R = −0.262, p = 0.162 | R = −0.193, p = 0.307 |
| Chronotropic index | R = 0.220, p = 0.243 | R = 0.330, p = 0.075 | R = 0.332, p = 0.073 | R = 0.333, p = 0.072 | R = 0.291, p = 0.118 | R = 0.419, p = 0.021 | R = 0.164, p = 0.386 |
| CPET parameters | | | | | | | |
| Exercise time | R = 0.318, p = 0.086 | R = 0.709, p < 0.001 | R = 0.544, p = 0.002 | R = 0.45, p = 0.013 | R = −0.099, p = 0.601 | R = 0.440, p = 0.015 | R = 0.38, p = 0.038 |
| Peak heart rate per kg | R = 0.262, p = 0.163 | R = 0.485, p = 0.007 | R = 0.384, p = 0.036 | R = 0.375, p = 0.041 | R = 0.377, p = 0.030 | R = 0.394, p = 0.031 | R = 0.277, p = 0.138 |
| Peak VO₂ per kg %N | R = 0.137, p = 0.469 | R = 0.541, p = 0.002 | R = 0.233, p = 0.216 | R = 0.185, p = 0.328 | R = −0.016, p = 0.933 | R = 0.222, p = 0.238 | R = 0.077, p = 0.687 |
| VE | R = 0.434, p = 0.017 | R = 0.369, p = 0.045 | R = 0.274, p = 0.143 | R = 0.249, p = 0.184 | R = 0.076, p = 0.690 | R = 0.298, p = 0.110 | R = 0.377, p = 0.04 |
| VE/VCO₂ | R = −0.012, p = 0.951 | R = −0.424, p = 0.019 | R = −0.240, p = 0.202 | R = −0.156, p = 0.411 | R = 0.119, p = 0.530 | R = −0.305, p = 0.102 | R = −0.197, p = 0.296 |
| Laboratory tests | | | | | | | |
| GGTP | R = −0.322, p = 0.083 | R = −0.245, p = 0.192 | R = −0.385, p = 0.036 | R = −0.346, p = 0.061 | R = −0.154, p = 0.415 | R = −0.368, p = 0.046 | R = −0.309, p = 0.096 |

Abbreviations: CPET, cardiopulmonary exercise test; GGTP, γ-glutamyl transpeptidase; HRR, heart rate reserve; HRV, heart rate variability; peak VO₂ per kg, peak oxygen uptake per kilogram; peak VO₂ (%N), percentage of predicted value for peak oxygen uptake; pNN50, percentage difference between adjacent NN intervals of >50 ms duration; rMSSD, root mean square of the differences of successive NN intervals; SDNN, standard deviation of all NN intervals; VE, minute ventilation; VE/VCO₂, peak ventilatory equivalent of CO₂. Significant results in bold.

3.5. Relationship between HRV, CPET, and Chronotropic Incompetence Parameters

The results of univariate analysis showed that Sat. O₂ rest, pNN50, and peak heart rate were associated with chronotropic index (the strongest relationship was observed for peak heart rate (R² = 0.54)). The results of multivariable analysis showed that all three variables were significant predictors of chronotropic index, accounting for 70% variability in chronotropic incompetence (Table 7).
Table 7. Association between oxygen saturation at rest, pNN50, peak heart rate, and chronotropic index.

|                        | Univariable Analysis |                        | Multivariable Analysis |                        |
|------------------------|----------------------|------------------------|------------------------|------------------------|
|                        | b                    | 95% CI                 | p-Value                | R²                     |
| Sat. O₂ rest           | 0.026                | (0.004–0.047)          | 0.02                   | 0.18                   | 0.021                  | (0.006–0.035)          | 0.006                  |
| pNN50                  | 0.016                | (0.003–0.029)          | 0.018                  | 0.19                   | 0.011                  | (0.003–0.020)          | 0.013                  |
| Peak heart rate        | 0.005                | (0.003–0.007)          | <0.001                 | 0.54                   | 0.004                  | (0.002–0.006)          | <0.001                 |

Abbreviations: HRR, heart rate reserve; pNN50, percentage difference between adjacent NN intervals of >50 ms duration; Sat. O₂, oxygen saturation; 95% CI, 95% confidence interval; b—coefficient from linear regression; R²—coefficient of determination.

4. Discussion

This study assessed the association between HRV, exercise capacity, and multi-organ complications in adults after undergoing FO. The findings revealed that patients after FO had significantly reduced HRV, implying a correlation between HRV parameters and age at the time of surgical intervention, the time since operation, reduced exercise capacity, and organ complications.

The activity of the ANS regulates HRV measures. In this study, 70% of patients from the study group showed a significant reduction in HRV parameters. These observations are in accordance with the earlier studies that investigated this issue in pediatric patient groups, but studies on adult groups are scarce [2,14,15,17,24].

In our study, adult patients who underwent FO showed a decrease in HRV parameters. This shows the association between age and reduced HRV. The reduction progressed over time after surgery. Similar observations were presented in the studies by Dahlqvist et al. [15] and Rydberg et al. [17]. The age of the patient at the time of the surgery plays a crucial role in the pathogenesis of arrhythmias. According to the literature, the best time for surgery in children with single-ventricle heart is up to 4 years of age [25–27].

Decreased HRV parameters were shown in children regardless of the surgical intervention approach utilized (intra-atrial lateral tunnel or extra-cardiac conduit) [15]. The findings of our study may be considered valuable and suggest that special attention should be paid for early qualification of children to FO. This observation is consistent with previous reports, including that of Abbott et al. [28], who proved that an increased preoperative heart rate is associated with an increased perioperative risk of heart damage and mortality.

The CPET results of this study revealed that reduced HRV parameters were associated with chronotropic incompetence and exercise capacity. Patients who had decreased HRV parameters had lower VO₂ peak and percentage of predicted value of VO₂ peak, and higher VE/VCO₂.

It has been shown that patients with overt heart failure had decreased VO₂ peak and increased VE/VCO₂, which are considered well-established predictors of mortality [29–31]. Furthermore, Kyoto et al. [32] reported a correlation between increased heart rate and decreased VO₂ peak, independent of age, sex, and heart disease. Silvilaired et al. [33] examined patients after tetralogy of Fallot and observed a relationship between the HRV parameters (low frequency and high frequency) and reduced VO₂ peak, which suggested that an impaired ANS response may be responsible for decreased exercise tolerance.

It has also been shown that VE/VCO₂ reflects the relationship between minute ventilation and CO₂ excretion [34]. This study revealed that patients with heart failure exhibited an elevated VE/VCO₂ that was associated with excessive minute ventilation in relation to exercise effort. One of the possible mechanisms explaining this phenomenon is an imbalance between the ANS and excessive sympathetic activity. Previous studies conducted among people with heart failure have shown that an increased ventilation response, expressed as higher VE/VCO₂, independently correlates with all HRV parameters [35].

Impaired chronotropic response is another issue observed in patients who have had FO [30,36]. Patients after FO have higher HRR, achieve shorter exercise time in CPET, and show lower VO₂ peak and higher VE/VCO₂ values. In this study, we attempted to explore whether the knowledge on reduced HRV parameters might be used to predict the
occurrence of organ complications. This assumption seems to be justified: our results confirmed that patients with lower pNN50, Sat. O2 rest, and peak heart rate had chronotropic incompetence and 70% probability of developing heart failure.

In patients after Fontan surgery, liver disorders commonly occur and may cause serious clinical complications [37,38]. In this study, we registered an increased level of GGTP and showed a correlation between GGTP and pNN50. This increased level of GGTP observed in patients after FO could be attributed to liver dysfunction or damage caused by chronic blood stagnation due to increased venous pressure (prevailing in Fontan’s circulation). To our knowledge, no studies have so far analyzed the relationship between reduced HRV parameters and liver dysfunction in patients after FO. However, several studies in the literature indicate reduced HRV values in patients with liver fibrosis [39–41]. These studies suggest that ANS dysfunction is associated with poor prognosis in this patient population. Furthermore, Bohogal et al. [41] showed that specific HRV parameters, regardless of the Model for End-Stage Liver Disease score, can predict mortality in patients with cirrhosis. The mechanism of ANS dysfunction in patients with liver fibrosis is still unknown and requires further research. However, the association between HRV and GGTP as observed in our study may be suspected to indirectly indicate the risk of developing liver dysfunction.

Holter ECG monitoring is relatively simple, generally available and non-invasive. It is performed in every patient after FO. HRV parameters have been identified as useful in various clinical scenarios [5,42]. We suppose that decreased HRV parameters may help to identify patients with specific organ complications. Decreased HRV parameters may be a risk of future arrhythmias and may indicate the need for regular follow-up in the case of heart failure development.

This retrospective study has several limitations to be acknowledged. Firstly, the number of patients was small and relatively mixed. Secondly, HRV parameters are highly sensitive to external factors. The norms for the analysis of HRV parameters and prognostically significant reduced values of these parameters in patients with congenital heart disease have not yet been developed. Therefore, further analyses with larger groups of patients are necessary.

5. Conclusions
This study revealed that patients after FO had reduced HRV parameters indicating ANS dysfunction, which was found to be associated with lower exercise tolerance and poor liver function. The data of the study suggest novel pathophysiological mechanisms that link HRV, physical performance, and organ damage in patients after FO.

Author Contributions: Conceptualization, M.O. and L.T.-P.; methodology, M.O., P.T.M. and L.T.-P.; software, M.O. and J.L.; validation, M.O., L.T.-P. and P.P.; formal analysis, M.O., P.T.M. and J.L.; investigation, M.O., L.T.-P. and P.P.; resources, M.O., L.T.-P. and P.P.; data curation, M.O. and J.L.; writing—original draft preparation, M.O.; writing—review and editing,: L.T.-P., J.P., P.T.M. and T.M.; visualization, M.O.; supervision, L.T.-P., J.P., T.M. and P.P.; project administration, L.T.-P. and P.P.; funding acquisition, L.T.-P. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by a grant of National Science Center (2017/27/B/NZ5/02186), to L.T.-P. The publication of this article was supported by the science found of the John Paul II Hospital, Cracow, Poland (no. FN/21/2021 to M.O).

Institutional Review Board Statement: This study was conducted according to guidelines of Declaration of Helsinki and was approved by the Bioethical Commission at the District Medical Chamber in Cracow (nr. 1072.6120.11.2017).

Informed Consent Statement: All patients gave a written informed consent.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available due to planned further publications.
Conflicts of Interest: The authors declare no conflict of interest.

References

1. Baumagartner, H.; De Backer, J.; Babu-Narayan, S.V.; Budts, W.; Chessa, M.; Diller, G.; Langle, B.; Kluni, J.; Lang, I.M.; Meijboom, F.; et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur. Heart J. 2021, 42, 563–645. [CrossRef]

2. Davos, C.H.; Francis, D.P.; Leenarts, M.F.E.; Sing-Chien, Y.; Wei, L.; Davlouros, P.A.; Wensel, R.; Coats, A.J.S.; Piepoli, M.; Seeram, N.; et al. Global impairment of cardiac autonomic nervous activity late after the Fontan operation. Circulation 2003, 108, 1180–1185. [CrossRef]

3. Kolcz, J.; Tomkiewicz-Pajak, L.; Wójcik, E.; Podolec, P.; Skalski, J. Prognostic significance of neurohumoral factors in early and late postoperative period after Fontan procedure. Interact. Cardiovasc. Thorac. Surg. 2011, 13, 40–45. [CrossRef] [PubMed]

4. Tomkiewicz-Pajak, L.; Hoffman, P.; Trojarska, O.; Bednarek, J.; Płazak, W.; Pajak, J.W.; Olszowska, L.; Komar, P.; Podolec, P.S. Long-term follow-up in adult patients after Fontan operation. Kardiochir. Torakochirurgia Pol. 2013, 10, 357–363.

5. Matusik, P.S.; Matusik, P.T.; Stein, P.K. Heart rate variability in patients with systemic lupus erythematosus: A systematic review and methodological considerations. Lupus 2018, 27, 1225–1239. [CrossRef] [PubMed]

6. Kleiger, R.E.; Miller, J.P.; Bigger, J.T.; Moss, A.J. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am. J. Cardiol. 1987, 59, 256. [CrossRef]

7. Nolan, J.; Batin, P.D.; Andrews, R.; Lindsay, S.J.; Brooksby, P.; Baig, W.; Flapan, A.D.; Cowley, A.; Prescott, R.J.; et al. Prospective study of heart rate variability and mortality in heart failure. Circulation 1998, 98, 1510. [CrossRef]

8. Bryniarski, L.; Kawwa, J.; Rajzer, M.; Stolarz, K.; Kawecka-Jaszcz, K. Zmienność rytmu zatokowego serca u pacjentów po zabiegach pomostowania aortalno-wieńcowego-wczesne i późne wyniki rehabilitacji kardiologicznej [Heart rate variability in patients after coronary artery bypass grafting—Early and long term effects of cardiac rehabilitation]. Przegl. Lek. 2002, 59, 699–702. (In Polish)

9. MeLeod, K.A.; Hillis, W.S.; Houston, A.B.; Wilson, N.; Trainer, A.; Neilson, J.; Doig, W.B. Reduced heart rate variability following repair of tetralogy of Fallot. Heart 1999, 81, 656–660. [CrossRef]

10. Zandstra, T.; Kiess, P.; Maan, A.; Man, S.-C.; Bootasma, M.; Vliegen, H.; Egorova, A.; Mertens, B.; Holman, E.; Schalij, M.; et al. Association between reduced heart rate variability components and supraventricular tachyarrhythmias in patients with a systemic right ventricle. Auton. Neurosci. 2020, 227, 106296. [CrossRef]

11. Heiberg, J.; Eckerström, F.; Rex, C.E.; Maagaard, M.; Melgaard, H.; Redington, A.; Gatzoulis, M.; Hjortdal, V.E. Heart rate variability is impaired in adults after closure of ventricular septal defect in childhood: A novel finding associated with right bundle branch block. Int. J. Cardiol. 2019, 274, 88–92. [CrossRef]

12. Moon, J.R.; Huh, J.; Song, J.; Kang, I.S.; Yang, J.H.; Jun, T.G.; Chang, S.A.; Park, S.W. Depression and heart rate variability in adults with cyanotic congenital heart disease. Circulation 2019, 140, A13169. [CrossRef]

13. Dahlqvist, J.A.; Wiklund, U.; Karlsson, M.; Hansséus, K.; Strömwall-Larsson, E.; Nygren, A.; Eliasson, H.; Rydberg, A. Sinus node dysfunction in patients with Fontan circulation: Could heart rate variability be predictor for pacemaker implantation? Pediatr. Cardiol. 2019, 40, 685–693. [CrossRef] [PubMed]

14. Buttera, G.; Bonnet, D.; Iserin, L.; Sidi, D.; Kachaner, J.; Villain, E. Total cavopulmonary and atriopulmonary connection are associated with reduced heart rate variability. Heart 1999, 82, 704–707. [CrossRef] [PubMed]

15. Dahlaqvist, J.A.; Karlsson, M.; Wiklund, U.; Hörnsten, R.; Strömwall-Larsson, E.; Berggren, H.; Hansséus, K.; Johansson, S.; Rydberg, A. Heart rate variability in children with Fontan circulation: Lateral tunnel and extracardiac conduit. Pediatr. Cardiol. 2021, 33, 307–315. [CrossRef]

16. Rydberg, A.; Karlsson, M.; Hornsten, R.; Wiklund, U. Can analysis of heart rate variability predict arrhythmia in children with Fontan circulation? Pediatr. Cardiol. 2008, 29, 50–55. [CrossRef]

17. Rydberg, A.; Rask, P.; Hornsten, R.; Teien, D. Heart rate variability in children with Fontan circulation. Pediatr. Cardiol. 2004, 25, 365–369. [CrossRef]

18. Bossers, S.S.M.; Duppen, N.; Kapusta, L.; Maan, A.; Duim, A.R.; Bogers Ad, J.J.C.; Hazekamp, M.G.; Iperen, G.; Helbing, W.A.; Blom, N.A. Comprehensive rhythm evaluation in a large contemporary Fontan population. Eur. J. Cardiothorac. Surg. 2015, 48, 833–840. [CrossRef]

19. Tomkiewicz-Pajak, L.; Podolec, P.; Drabik, L.; Pajak, J.; Kolcz, J.; Plazak, W. Single ventricle function and exercise tolerance in adult patients after Fontan operation. Acta. Cardiol. 2014, 69, 155–160. [CrossRef]

20. Wilkoff, B.L.; Corey, J.; Blackburn, G. A mathematical model of cardiac chronotropic response to exercise. J. Electrophysiol. 1989, 3, 176–180. [CrossRef]

21. Straburszyńska-Migaj, E. Spiroergometric exercise test. In Cardiology Handbook of the Polish Cardiac Society; Ponikowski, P., Hoffmen, P., Witkowski, A., Lipiec, P., Eds.; Via Medica: Gdańsk, Poland, 2019; pp. 87–94. (In Polish)

22. Guazzi, M.; Adams, V.; Conraads, V.; Vivanie, C.; Martin, H.; Mezzani, A.; Vanhees, L.; Arena, R.; Fletcher, G.F.; Forman, D.F.; et al. Clinical recommendations for cardiopulmonary exercise testing data assessment in specific patient populations. Circulation 2012, 126, 2261–2274. [CrossRef]

23. Heart rate variability: Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American society of Pacing Electrophysiology. Circulation 1996, 93, 1043–1065. [CrossRef]
24. Ohuchi, H.; Hasegawa, S.; Yasuda, K.; Yamada, O.; Ono, Y.; Echigo, S. Severely impaired cardiac autonomic nervous activity after the Fontan operation. *Circulation* **2001**, *104*, 1513–1518. Erratum in: *Circulation* **2004**, *109*, 3257.

25. Hofbeck, M.; Koch, A.; Buheitel, G.; Gerling, S.; Rauch, R.; Weyand, M.; Singer, H. Spätpostoperative Herzrhythmusstörungen nach totaler cavopulmonaler Anastomose und ihre Beziehung zum Operationsalter der Patienten [Late postoperative cardiac arrhythmias after total cavopulmonary anastomosis and correlation with age of the patients at operation]. *Z. Kardiol.* **2000**, *89*, 788–794. (In German) [CrossRef]

26. Malec, E.; Zajač, A.; Paják, J. The results of one-stage and two-stage Fontan operation in children with single ventricle. *Kardiol. Pol.* **1998**, *48*, 23–30.

27. Moll, J.A.; Ostrowska, K.; Dobrowolski, J. Diagnostic and therapeutic procedures in single ventricle—Own experience. *Przegląd. Ped.* **2000**, *30*, 140–144.

28. Abbott, T.E.F.; Minto, G.; Lee, A.M.; Pearse, R.M.; Ackland, G.L. POM-HR, POMO-O and OPTIMISE study groups. Elevated preoperative heart rate is associated with cardiopulmonary and autonomic impairment in high-risk surgical patients. *Br. J. Anaesth.* **2017**, *119*, 87–94. [CrossRef]

29. Mantegazza, V.; Apostolo, A.; Hager, A. Cardiopulmonary exercise testing in adult congenital heart disease. *Ann. Am. Thorac. Soc.* **2017**, *14*, S93–S101. [CrossRef]

30. Takken, T.; Blank, A.C.; Hulzebos, E.H.; Van Brussel, M.; Groen, W.G.; Holders, P.J. Cardiopulmonary exercise testing in congenital heart diseases: (Contra)indication and interpretation. *Neth. Heart J.* **2009**, *10*, 385–392. [CrossRef] [PubMed]

31. Myers, J.; Arena, R.; Dewey, F.; Bensimhon, D.; Abella, J.; Hsu, L.; Chase, P.; Guazzi, M.; Peberdy, M.A. A cardiopulmonary exercise testing score for predicting outcomes in patients with heart failure. *Am. Heart J.* **2008**, *156*, 1177–1183. [CrossRef] [PubMed]

32. Kato, Y.; Suzuki, S.; Uejima, T.; Semba, H.; Nagayama, O.; Hayama, E.; Yamashita, T. The relationship between resting heart rate and peak VO2: A comparison of atrial fibrillation and sinus rhythm. *Eur. J. Prev. Cardiol.* **2016**, *23*, 1429–1436. [CrossRef] [PubMed]

33. Silvilairat, S.; Wongsathikun, J.; Sittiwangkul, R.; Pongprot, Y.; Chattipakorn, N. Heart rate variability and exercise capacity of patients with repaired tetralogy of Fallot. *Pediatr. Cardiol.* **2002**, *23*, 80–81. [PubMed]

34. Tomkiewicz-Pajak, L.; Podolec, P.; Kostkiewicz, M.; Tracz, W. Lung function and exercise tolerance in patients with heart failure. *Acta Cardiol.* **2002**, *57*, 80–81. [PubMed]

35. Ponikowski, P.; Chua, T.P.; Pieplo, M.; Banasiak, W.; Anker, S.D.; Szelmej, R.; Molenda, W.; Wrabec, K.; Capucci, A.; Coats, A.J. Ventilatory response to exercise correlates with impaired heart rate variability in patients with chronic congestive heart failure. *Am. J. Cardiol.* **1998**, *82*, 338–344. [CrossRef]

36. Okołoska, M.; Skubera, M.; Matusik, P.; Plazak, W.; Pajak, J.; Róg, B.; Podolec, P.; Tomkiewicz-Pajak, L. Chronotropic incompetence causes multiple organ complications in adults after the Fontan procedure. *Kardiol. Pol.* **2021**, *79*, 410–417. [CrossRef] [PubMed]

37. Smaj-Puskas, M.; Skubera, M.; Wilkosz, T.; Wryński, T.; Kołcz, J.; Olszowska, M.; Podolec, P.; Tomkiewicz-Pajak, L. Noninvasive assessment of liver status in adult patients after Fontan procedure. *Pol. Arch. Intern. Med.* **2019**, *129*, 181–188. [PubMed]

38. Kaulitz, R.; Haber, P.; Sturm, E.; Schäfer, J.; Hofbeck, M. Serial evaluation of hepatic function profile after Fontan operation. *Herz* **2014**, *39*, 98–104. [CrossRef]

39. Ates, F.; Topal, E.; Kosar, F.; Karıncaoğlu, M.; Yıldırım, B.; Aksoy, Y.; Aladag, M.; Harputluoğlu, M.M.; Demirel, U.; Alan, H.; et al. The relationship of heart rate variability with severity and prognosis of cirrhosis. *Dig. Dis. Sci.* **2006**, *51*, 1614–1618. [CrossRef] [PubMed]

40. Mani, A.R.; Montagnese, S.; Jackson, C.D.; Jenkins, C.W.; Head, I.M.; Stephens, R.C.; Moore, K.P.; Morgan, M.Y. Decreased heart rate variability in patients with cirrhosis relates to the presence and degree of hepatic encephalopathy. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2009**, *296*, G330–G338. [CrossRef]

41. Bhogal, A.S.; De Rui, M.; Pavanello, D.; El-Azizi, I.; Rowshana, S.; Amadio, P.; Montagnese, S.; Mani, A.R. Which heart rate variability index is an independent predictor of mortality in cirrhosis? *Dig. Liver Dis.* **2019**, *51*, 695–702. [CrossRef]

42. Marinković, M.; Mijuović, N.; Vučićević, V.; Steffel, J.; Potpara, T.S. A square root pattern of changes in heart rate variability during the first year after circumferential pulmonary vein isolation for paroxysmal atrial fibrillation and their relation with long-term arrhythmia recurrence. *Kardiol. Pol.* **2020**, *78*, 209–218. [CrossRef]